Association of hormonal factors and preinvasive mammary lesions increase the risk of sporadic breast cancer (BC) incidence. Indeed, the mitogenic activity of estrogens and their role as a promoter of BC was confirmed by epidemiological, clinical, and experimental studies (1). Preinvasive mammary lesions frequently precede the development of invasive BC. They correspond to nonproliferative and proliferative benign breast disease without or with atypia and ductal carcinoma in-situ (DCIS) (2).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
The Endogenous Hormones and Breast Cancer Collaborative Group (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94:606–16.
Tavassoli FA, Devilee P (2003) World Health Organization Classification of Tumours. Pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC Press.
Vogelstein B, Kinzler KW (1993) The multistep nature of cancer. Trends Genet 9:138–41.
Dupont WD, Page DL (1985) Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 312:146–51.
Hartmann LC, Sellers TA, Frost MH, et al. (2005) Benign breast disease and the risk of breast cancer. N Engl J Med 353(3):229–37.
Fisher B, Costantino JP, Wickerham DL, et al. (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 16;90(18):1371–88.
Martino S, Cauley JA, Barrett-Connor E, et al. (2004) Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 1;96(23):1751–61.
Vogel VG, Costantino JP, Wickerham DL el al. (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 21;295(23):2727–41.
Enmark E, Pelto-Huikko M, Grandien K, et al. (1997) Human estrogen receptor ß-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab 82:4258–65.
Ogawa S, Inoue S, Watanabe T et al. (1998) Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor of estrogen action in human. Nucleic Acids Res 26:3505–12.
Leyghe E, Dotzlaw H, Waton PH, et al. (1998) Altered estrogen receptor alpha and beta messenger RNA expression during human breast tumorigenesis. Cancer Res 1;58(15):3197–201.
Pujol P, Rey JM, Nirde P, et al. (1998) Differential expression of estrogen receptor alpha and beta as a potential marker of ovarian carcinogenesis. Cancer Res 58:5367–73.
Esslimani-Sahla M, Simony-Lafontaine J, Kramar A, et al. (2004) ERß level helps to predict Tam resistance in breast cancer but not its ERßcx variant. Clin Cancer Res 10:5769–76.
Skliris GP, Leygue E, Curtis–Snell L, et al. (2006) Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours. Br J Cancer 95(5):616–26.
Sorlie T, Perou CM, Tibshirani R, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869–74.
Leygue E, Dotzlaw H, Watson PH, et al. (1999) Expression of estrogen receptor beta1, beta2, and beta5 messenger RNAs in human breast tissue. Cancer Res 15;59(6):1175–9.
Rochefort H, Cavailles V, Augereau P, et al. (1989) Overexpression and hormonal regulation of pro-cathepsin D in mammary and endometrial cancer. J Steroid Biochem 34(1–6):177–82.
Spyratos F, Maudelonde T, Brouillet JP, et al. (1989) An independent prognostic factor for metastasis of breast cancer. Lancet ii:1115–18.
Khan SA, Rogers MA, Khurana KK, et al. (1998) Estrogen receptor expression in benign breast epithelium and breast cancer risk. J Natl Cancer Inst 90:37–42.
Roger P, Esslimani Sahla M, Makela S, et al. (2001) Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res 61:2537–2541.
Shaaban AM, Jarvis C, Moore F, et al. (2005) Prognostic significance of estrogen receptor Beta in epithelial hyperplasia of usual type with known outcome. Am J Surg Pathol 29(12):1593–9.
Esslimani Sahla M, Kramar A, Simony-Lafontaine J, et al. (2005) Increased estrogen receptor beta cx expression during mammary carcinogenesis. Clin Cancer Res 11:3170–74.
Matthews J, Gustafsson JA (2003) Estrogen signaling: a subtle balance between ER alpha and ER beta. Mol Interv 3(5):281–92. Review.
Lazennec G, Bresson D, Lucas A, et al. (2001) ERß inhibits proliferation and invasion of breast cancer cells. Endocrinology 142:4120–30.
Zhao C, Lam EW-F, Sunters A, et al. (2003) Expression of estrogen receptor ß isoforms in normal breast epithelial cells and human breast cancer: regulation by methylation. Oncogene 22:7600–6.
Rochefort H, Garcia M, Glondu M, et al. (2000) Cathepsin D in breast cancer: Mechanisms and clinical applications. A 1999 overview. Clin Chim Acta 291(2):157–70.
Maudelonde T, Khalaf S, Garcia M, et al. (1988) Immunoenzymatic assay of Mr 52, OOO cathepsin D in 182 breast cancer cytosols. Low correlation with other prognostic parameters. Cancer Res 48:462–6.
Roger P, Daures JP, Maudelonde T, et al. (2000) Dissociated overexpression of cathepsin-D and estrogen receptor alpha in preinvasive mammary tumors. Hum Pathol 31(5):593–600.
Shaaban AM, O’Neill PA, Davies MP, et al. (2003) Declining estrogen receptor-beta expression defines malignant progression of human breast neoplasia. Am J Surg Pathol 27(12):1502–12.
Simpson PT, Reis-Filho JS, Gale T, et al. (2005) Molecular evolution of breast cancer. J Pathol 205(2):248–54. Review.
Brouillet JP, Dujardin MA, Chalbos D, et al. (2001) Analysis of the potential contribution of estrogen receptor (ER) α in ER cytosolic assay of breast cancer. Int J Cancer 95:205–8.
Clarke Rb, Howell A, Potten CS, et al. (1997) Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 15;57(22):4987–91.
Rochefort H, Capony F, Garcia M, et al. (1987) Estrogen-induced lysosomal proteases secreted by breast cancer cells. A role in carcinogenesis? J Steroid Biochem 34:177–82.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer
About this chapter
Cite this chapter
Roger, P., Esslimani-Sahla, M., Delfour, C., Lazennec, G., Rochefort, H., Maudelonde, T. (2008). Expression of Estrogen Receptors α and β in Early Steps of Human Breast Carcinogenesis. In: Li, J.J., Li, S.A., Mohla, S., Rochefort, H., Maudelonde, T. (eds) Hormonal Carcinogenesis V. Advances in Experimental Medicine and Biology, vol 617. Springer, New York, NY. https://doi.org/10.1007/978-0-387-69080-3_13
Download citation
DOI: https://doi.org/10.1007/978-0-387-69080-3_13
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-69078-0
Online ISBN: 978-0-387-69080-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)